Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 9 » Issue 1

A US database study characterizing patients initiating a budesonide–formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease

Authors Kern DM, Williams SA, Tunceli O, Wessman C, Zhou S, Pethick N, Elhefni H, Trudo F

Received 20 March 2014

Accepted for publication 2 May 2014

Published 18 July 2014 Volume 2014:9(1) Pages 775—783

DOI https://doi.org/10.2147/COPD.S64491

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

David M Kern,1 Setareh A Williams,2 Ozgur Tunceli,1 Catrin Wessman,3 Siting Zhou,1 Ned Pethick,2 Hanaa Elhefni,2 Frank Trudo2

1HealthCore Inc., 2AstraZeneca, Wilmington, DE, USA; 3AstraZeneca, Mölndal, Sweden

Objective: To compare clinical and demographic characteristics, resource utilization and costs of chronic obstructive pulmonary disease (COPD) patients prior to initiating budesonide–formoterol combination (BFC) or tiotropium-maintenance therapy.
Materials and methods: This cross-sectional study used claims-based diagnosis to identify COPD patients in the HealthCore Integrated Research Database who initiated BFC or tiotropium therapy between March 1, 2009 and January 31, 2012 (intake period); the index date was defined as the initial prescription fill for either agent. Patients diagnosed with respiratory tract cancer or receiving inhaled corticosteroids/long-acting β2-adrenergic agonists or tiotropium in 12 months prior to index date were excluded. Categorical variables were evaluated with Χ2 tests; mean cost differences were evaluated using γ-regression.
Results: Overall, 6,940 BFC and 10,831 tiotropium patients were identified. The BFC group was younger (mean age 64 versus 67 years), with a greater proportion of females (54% versus 51%). BFC-treated patients had more comorbid respiratory conditions, including asthma (25% versus 13%), but fewer comorbid cardiovascular conditions, including atherosclerosis (7% versus 10%) and myocardial infarction (4% versus 6%). A greater proportion of BFC patients received prior respiratory medication, including oral corticosteroids (46% versus 35%) and short-acting β2-agonists (44% versus 35%). Tiotropium-treated patients had a greater mean number of COPD-related outpatient visits (4.6 versus 4.1). BFC-treated patients had lower total all-cause ($17,259 versus $17,926) and COPD-related ($1,718 versus $1,930) health care costs, driven by lower all-cause and COPD-related inpatient expenditures.
Conclusion: Initiators of BFC or tiotropium showed differences in clinical and demographic characteristics and health care utilization and costs prior to starting COPD maintenance therapy.

Keywords: observational study, retrospective analysis, chronic respiratory condition, outcome research, health care utilization and costs

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

A validation of clinical data captured from a novel Cancer Care Quality Program directly integrated with administrative claims data

Kern DM, Barron JJ, Wu B, Ganetsky A, Willey VJ, Quimbo RA, Fisch MJ, Singer J, Nguyen A, Mamtani R

Pragmatic and Observational Research 2017, 8:149-155

Published Date: 26 August 2017

Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments

Trudo F, Kern DM, Davis JR, Tunceli O, Zhou S, Graham EL, Strange C, Williams SA

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2055-2066

Published Date: 28 September 2015

Validation of an administrative claims-based diagnostic code for pneumonia in a US-based commercially insured COPD population

Kern DM, Davis J, Williams SA, Tunceli O, Wu B, Hollis S, Strange C, Trudo F

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1417-1425

Published Date: 23 July 2015

Readers of this article also read:

Systemic signs of neutrophil mobilization during clinically stable periods and during exacerbations in smokers with obstructive pulmonary disease

Andelid K, Andersson A, Yoshihara S, Åhrén C, Jirholt P, Ekberg-Jansson A, Lindén A

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1253-1263

Published Date: 30 June 2015

Whole-body vibration improves functional capacity and quality of life in patients with severe chronic obstructive pulmonary disease (COPD): a pilot study

Braz Júnior DS, Dornelas de Andrade A, Teixeira AS, Cavalcanti CA, Morais AB, Marinho PE

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:125-132

Published Date: 12 January 2015

Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD

Postma DS, Roche N, Colice G, Israel E, Martin RJ, van Aalderen WMC, Grigg J, Burden A, Hillyer EV, von Ziegenweidt J, Gopalan G, Price D

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1163-1186

Published Date: 17 October 2014

Characteristics and self-rated health of overlap syndrome

Chung JW, Kong KA, Lee JH, Lee SJ, Ryu YJ, Chang JH

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:795-804

Published Date: 21 July 2014

Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease

Brockwell C, Ampikaipakan S, Sexton DW, Price D, Freeman D, Thomas M, Ali M, Wilson AM

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:715-721

Published Date: 9 July 2014